57684-32-9

Basic information

• Product Name: N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine
• Synonyms: N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine;1-(1H-Benzotriazol-1-yl)-N,N-dibenzylmethanamine;1H-Benzotriazole-1-methanamine, N,N-bis(phenylmethyl)-
• CAS NO: 57684-32-9
• Molecular Formula: C₂₁H₂₀N₄
• Molecular Weight: 328.4103
• Mol File: 57684-32-9.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine(57684-32-9)
• EPA Substance Registry System: N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine(57684-32-9)

Safety Data

• Hazardous Substances Data: 57684-32-9(Hazardous Substances Data)

Usage

General Description

N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine is a chemical compound with a complex structure consisting of a benzyl group attached to a phenylmethylamine moiety by a benzotriazole linker. N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylMethanaMine belongs to the class of organic compounds known as bridged PhC1 compounds. It is used in scientific research as a ligand for various metal catalysts and in the development of pharmaceuticals. The compound may have potential pharmacological activities, although further studies are needed to fully understand its biological effects.

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 50-00-0 formaldehyd 
• 103-49-1 dibenzylamine 
• 28539-02-8 1-Hydroxymethyl-1H-benzotriazole 

Downstream Products

• 162735-89-9 1-<1-(Benzotriazol-1-yl)-3-(dibenzylamino)propyl>-2-pyrrolidinone 
• 127137-03-5 3-Dibenzylamino-2,2-dimethyl-propionic acid ethyl ester 
• 10479-25-1 N,N-dibenzylethanamine 
• 620-40-6 tribenzylamine 
• 5636-54-4 N,N-dibenzyl-2-phenylethan-1-amine 
• 102-05-6 N-methyldibenzylamine 
• 108898-31-3 ethyl 3-(dibenzylamino)propanoate 
• 68452-42-6 N,N-dibenzyl-1-phenylprop-1-yn-3-amine 
• 541547-36-8 ethyl N,N-(dibenzyl)-2,2-difluoro-3,3-aminopropanoate 
• 162736-17-6 1-(3-Dibenzylamino-1-phenyl-propyl)-2-phenyl-pyrrolidin-2-ol 
• 890147-31-6 methyl 3-(N,N-dibenzylamino)-2,2-difluoropropionate 
• 957208-09-2 3-(dibenzylamino)-2-fluoropropanoic acid ethyl ester 
• 1448049-58-8 N,N-dibenzyl-2,7-dimethyl-3-methylene-6-octenylamine 
• 1448049-55-5 N,N-dibenzyl-2,3-dimethyl-3-butenylamine 

Relevant articles and documents

NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.